Browse News
Filter News
Found 554,237 articles
-
Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.
-
The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.
-
Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.
-
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, recently developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
-
The administration sees the push for transparency as a tool to help consumers control the costs of their health care.
-
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
-
On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.
-
Research Roundup for Friday, May 24.
-
New York City-based Tonix Pharmaceuticals announced it has in-licensed a Phase II drug, TNX-1300, from Columbia University. TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine abusers.
-
BioSpace Movers and Shakers, May 24
5/24/2019
Biopharma companies from across the globe strengthen their leadership teams with key executive appointments. -
Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.
-
ProfNet Experts Available on Acupressure, CBD Benefits, Animal Rights, More
5/24/2019
Experts from the ProfNet network who are available to discuss timely issues in your coverage area.
-
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
5/24/2019
Full Results from Phase 3 ARTEMIS Study Will Be Featured
-
Green Growth Brands Announces Grant of Restricted Share Units
5/24/2019
Green Growth Brands, Inc. is pleased to announce that its board of directors has approved the grant of an aggregate of 595,000 restricted share units under the Company's equity incentive plan to certain of its employees.
-
FLX Bio Announces Name Change to RAPT Therapeutics
5/24/2019
Name Reflects Our Focus on Defeating Cancer and Allergic Inflammatory Diseases
-
Epilepsy Foundation Awards $200,000 in Grants to Support Development of Innovative Products for Epilepsy Diagnosis & Treatment
5/24/2019
IBE President Dr. Martin Brodie Receives Epilepsy Lifetime Accelerator Award at AEDD
-
Kelyniam Global Announces 510(k) Clearance for Integrated Fixation System for Custom Skull Implants
5/24/2019
Kelyniam Global, a maker of custom cranial and craniofacial implants, announced that it has received premarket approval from the Food and Drug Administration for a new 510 application that allows for unique modifications to their PEEK cranio-maxillofacial implant product line.
-
Novocure to Participate in the Jefferies 2019 Global Healthcare Conference
5/24/2019
Novocure announced that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.
-
Alpine Immune Sciences to Present at Upcoming Investor Conferences
5/24/2019
Alpine Immune Sciences, Inc. announced the company will participate in three upcoming investor conferences in June.
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
5/24/2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.